Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,758 matching trials from the live ClinicalTrials.gov search.
Conditions
Small Cell Lung Cancer
Interventions
Placebo for dexamethasone, Placebo for rovalpituzumab tesirine, Rovalpituzumab tesirine, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
54
States / cities
Huntsville, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 48 more
Conditions
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Carboplatin, Cisplatin, Computed Tomography, Fluorouracil, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Positron Emission Tomography, Quality-of-Life Assessment, Radiation Therapy
Drug · Procedure · Biological + 2 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
51
States / cities
Tampa, Florida • Atlanta, Georgia • Boise, Idaho + 39 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bryostatin 1, cisplatin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Conditions
Pancreatic Cancer
Interventions
cisplatin, gemcitabine hydrochloride, surgical procedure, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Conditions
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Carboplatin, Cisplatin, Durvalumab, Etoposide, Hypofractionated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Drug · Biological · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Active, not recruiting Phase 2 Interventional

Cisplatin+Pembrolizumab+RT in Vulvar Cancer

NCT04430699
Conditions
Vulvar Cancer, Vulvar Squamous Cell Carcinoma
Interventions
Cisplatin, Pembrolizumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Lung Cancer
Interventions
carboplatin, cisplatin, gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
13
States / cities
Atlanta, Georgia • Des Moines, Iowa • Papillion, Nebraska + 8 more
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
evorpacept, pembrolizumab, Cisplatin/Carboplatin; 5FU
Drug
Lead sponsor
ALX Oncology Inc.
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
13
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 10 more
Conditions
Prostate Cancer
Interventions
filgrastim, carmustine, cisplatin, melphalan, vinorelbine tartrate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Endometrial Neoplasms
Interventions
pembrolizumab, carboplatin, paclitaxel, docetaxel, cisplatin
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
35
States / cities
Phoenix, Arizona • La Jolla, California • Riverside, California + 28 more
Conditions
Non-small Cell Lung Cancer
Interventions
Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel, Placebo in combination with cisplatin and docetaxel or paclitaxel
Drug
Lead sponsor
BioNumerik Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
Birmingham, Alabama • Columbia, Missouri • Philadelphia, Pennsylvania + 1 more
Conditions
Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7
Interventions
Carboplatin, Cisplatin, Internal Radiation Therapy, Paclitaxel, Quality-of-Life Assessment, Radiation Therapy
Drug · Radiation · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
655
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 407 more
Conditions
Cervical Cancer
Interventions
cisplatin, gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
105
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more
Conditions
Small Cell Lung Cancer
Interventions
M3814, Cisplatin, Etoposide
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
16
States / cities
Mesa, Arizona • Santa Rosa, California • Whittier, California + 12 more
Conditions
Lung Cancer
Interventions
cisplatin, gemcitabine hydrochloride, prinomastat
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
La Jolla, California
Active, not recruiting Early Phase 1 Interventional

Bladder Preservation or Cystectomy for MIBC

NCT07821177
Conditions
Muscle-Invasive Bladder Carcinoma, Bladder Cancer, Urothelial Carcinoma
Interventions
Gemzar, Cisplatin, Adrucil, Mitomycin, Radical Cystectomy
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Interventions
Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV, Bevacizumab, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
85
States / cities
Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 67 more
Conditions
Urothelial Carcinoma
Interventions
AEZS-108, AEZS-108 at MTD
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Miami, Florida • Philadelphia, Pennsylvania
Terminated Phase 2Phase 3 Interventional Results available

Nintedanib (BIBF 1120) in Mesothelioma

NCT01907100
Conditions
Mesothelioma
Interventions
Nintedanib, Pemetrexed, Cisplatin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Littleton, Colorado + 7 more
Conditions
Cervical Cancer
Interventions
cisplatin, pemetrexed disodium
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Up to 120 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • Jackson, Mississippi + 7 more
Conditions
NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer, Lung Cancer (NSCLC), Metastatic NSCLC - Non-Small Cell Lung Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer
Interventions
zoldonrasib, Placebo, pembrolizumab, pemetrexed + cisplatin /carboplatin
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Anchorage, Alaska • Fort Lauderdale, Florida • Plantation, Florida
Conditions
Localized Osteosarcoma, Metastatic Osteosarcoma
Interventions
Cisplatin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate, Peginterferon Alfa-2b, Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Conventional Surgery
Drug · Biological · Other + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
5 Years to 40 Years
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
186
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 132 more
Conditions
Advanced Solid Tumor, NSCLC
Interventions
CLN-619, Pembrolizumab, Paclitaxel, Carboplatin AUC 6, pemetrexed, Datopotamab deruxtecan-dlnk (Dato-DXd)
Drug
Lead sponsor
Cullinan Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
12
States / cities
Birmingham, Alabama • Duarte, California • Irvine, California + 9 more
Conditions
Biliary Tract Cancer
Interventions
Durvalumab, Gemcitabine monotherapy, Gemcitabine + cisplatin, Gemcitabine + oxaliplatin, Gemcitabine + carboplatin, Gemcitabine + cisplatin + S-1, Gemcitabine + S-1, Gemcitabine + cisplatin + albumin-bound paclitaxel
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Mobile, Alabama • Orange, California • Washington D.C., District of Columbia + 1 more